Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2013.0254


Statins for reducing cancer death risk? Molecular evidence vs. statistics .

William CS CHO, MD, PhD.

Affiliation: William CS Cho, Scientific Officer, Department of Clinical Oncology, Queen Elizabeth Hospital, Room 1305, 13/F, Block R, 30 Gascoigne Road, Kowloon, Hong Kong.


With aging of the population, and a Western-type lifestyle, cancer has been the leading health problem in the developed world and a future threat for the society. The costs associated with cancer screening, prevention and particularly multidisciplinary treatment are being increased exponentially. Latest tumor-targeted therapies are very expensive and new drugs continuously are being developed and approved a further dramatic increase of insurance and governmental costs are expected. Hundreds of billions are funding the research for fighting cancer. But as latest cancer genome-based research reveals, the war against cancer is a hard task because of high complexity of the disease. Given this daunting challenge, can statins, which are the most commonly prescribed class of drugs worldwide, reduce mortality as a recently published study in the New England Journal of Medicine 1 , has suggested? Is such a simplified statistics from a database sufficient to save millions of lives instead of the effort to overcome myriad problems in understanding the dynamics of complex molecular mechanisms underlying cancer genome structure and function?

(Citation: Gastric & Breast Cancer 2012; 12(1): xx-xx)



You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 14 January 2013